GLPwatch
Papers (9189)
Page 72 of 154, ranked by citation count.
- The Use of Semaglutide in Patients With Renal Failure-A Retrospective Cohort Study.
- Combination therapy with exenatide decreases the dapagliflozin-induced changes in brain responses to anticipation and consumption of palatable food in patients with type 2 diabetes: A randomized controlled trial.
- Exendin-4 regulates endoplasmic reticulum stress to protect endothelial progenitor cells from high-glucose damage.
- Initial Experience with Alternate-Day Liraglutide for Weight Regain Following Bariatric Surgery.
- The glucagon-like peptide-1-based therapeutics exenatide and saxagliptin did not cause detrimental effects on the pancreas in mice, rats, dogs and monkeys.
- Retatrutide showing promise in obesity (and type 2 diabetes).
- SAVOR-TIMI to SUSTAIN-6: a critical comparison of cardiovascular outcome trials of antidiabetic drugs.
- Pharmacological Treatment of Binge Eating Disorder and Frequent Comorbid Diseases.
- Protective Effects of Liraglutide and Linagliptin in C. elegans as a New Model for Glucose-Induced Neurodegeneration.
- Defining the role of GLP-1 receptor agonists for individualized treatment of Type 2 diabetes.
- Emerging role of GLP-1 receptor agonists in the treatment of obesity.
- A GIP/xenin hybrid in combination with exendin-4 improves metabolic status in db/db diabetic mice and promotes enduring antidiabetic benefits in high fat fed mice.
- Pharmacodynamical effects of orally administered exenatide nanoparticles embedded in gastro-resistant microparticles.
- Partial agonism improves the anti-hyperglycaemic efficacy of an oxyntomodulin-derived GLP-1R/GCGR co-agonist.
- Obesity-induced alterations in the gut microbiome in female mice fed a high-fat diet are antagonized by dietary supplementation with a novel, wax ester-rich, marine oil.
- Clinical effects of once-weekly exenatide for the treatment of type 2 diabetes mellitus.
- Effectiveness and safety of liraglutide after three years of treatment.
- Efficacy and safety of dulaglutide monotherapy compared with glimepiride in Chinese patients with type 2 diabetes: Post-hoc analyses of a randomized, double-blind, phase III study.
- Proinflammatory switch from Gαs to Gαi signaling by Glucagon-like peptide-1 receptor in murine splenic monocyte following burn injury.
- Effect of liraglutide vs. NPH in combination with metformin on blood glucose fluctuations assessed using continuous glucose monitoring in patients with newly diagnosed type 2 diabetes.
- Real-world effectiveness of IDegLira compared with intensified conventional insulin therapy in adults with type 2 diabetes: a retrospective cohort study.
- A novel anti-obesity mechanism for liraglutide by improving adipose tissue leptin resistance in high-fat diet-fed obese mice.
- LEADER-4: blood pressure control in patients with type 2 diabetes and high cardiovascular risk: baseline data from the LEADER randomized trial.
- Acute effects of the glucagon-like peptide-1 receptor agonist, exenatide, on blood pressure and heart rate responses to intraduodenal glucose infusion in type 2 diabetes.
- Pharmacotherapy for obesity in individuals with type 2 diabetes.
- Effects of exenatide therapy on insulin resistance in the skeletal muscles of high-fat diet and low-dose streptozotocin-induced diabetic rats.
- GLP-1 receptor agonists are a transformative prehabilitation tool for weight loss in obese patients undergoing elective hernia repair.
- Optimization of Metformin in the GRADE Cohort: Effect on Glycemia and Body Weight.
- Role of ERp46 in β-cell lipoapoptosis through endoplasmic reticulum stress pathway as well as the protective effect of exendin-4.
- Exendin‑4 inhibits lipotoxicity‑induced oxidative stress in β‑cells by inhibiting the activation of TLR4/NF‑κB signaling pathway.
- Efficacy and safety analyses across 4 subgroups combining low and high age and body mass index groups in Japanese phase 3 studies of dulaglutide 0.75 mg after 26 weeks of treatment.
- Molecular Characterisation of Small Molecule Agonists Effect on the Human Glucagon Like Peptide-1 Receptor Internalisation.
- Prevalence Patterns of Body Contouring Procedures Among Injectable Glucagon-like Peptide-1 Receptor Agonist Users.
- Chronic peptide-based GIP receptor inhibition exhibits modest glucose metabolic changes in mice when administered either alone or combined with GLP-1 agonism.
- Effects of liraglutide vs. lifestyle changes on soluble suppression of tumorigenesis-2 (sST2) and galectin-3 in obese subjects with prediabetes or type 2 diabetes after comparable weight loss.
- Population pharmacodynamic modeling of exenatide after 2-week treatment in STZ/NA diabetic rats.
- Liraglutide for treating type 1 diabetes.
- Liraglutide use and evaluation of pancreatic outcomes in a US commercially insured population.
- Characterisation and antidiabetic utility of a novel hybrid peptide, exendin-4/gastrin/xenin-8-Gln.
- Exenatide mitigates inflammation and hypoxia along with improved angiogenesis in obese fat tissue.
- Tolerability and safety of the new anti-obesity medications.
- Automated recognition and quantification of pancreatic islets in Zucker diabetic fatty rats treated with exendin-4.
- A Comparison of New Pharmacological Agents for the Treatment of Obesity.
- The effects of Exendin-4 on bone marrow-derived mesenchymal cells.
- Monotreme glucagon-like peptide-1 in venom and gut: one gene - two very different functions.
- The effects of a GLP-1 analog liraglutide on reward value and the learned inhibition of appetitive behavior in male and female rats.
- Differing effects of liraglutide on gastric emptying in Japanese patients with type 2 diabetes.
- Efficacy of Exenatide Plus Pioglitazone Vs Basal/Bolus Insulin in T2DM Patients With Very High HbA1c.
- Albumin as a drug delivery and diagnostic tool and its market approved products.
- Weight and Glycemic Control Outcomes of Bariatric Surgery and Pharmacotherapy in Patients With Melanocortin-4 Receptor Deficiency.
- The effect of metformin combined with liraglutide on gut microbiota of Chinese patients with type 2 diabetes.
- The Role of Glucagon-Like Peptide-1 Receptor Agonists in Type 2 Diabetes in Asia.
- Euglycemic Ketoacidosis From Semaglutide in a Patient Without Diabetes.
- Once-weekly IcoSema versus multiple daily insulin injections in type 2 diabetes management (COMBINE 3): an open-label, multicentre, treat-to-target, non-inferiority, randomised, phase 3a trial.
- Role of glucagon-like peptide- 1 in vascular endothelial dysfunction.
- In vitro metabolic stability of exendin-4: pharmacokinetics and identification of cleavage products.
- Semaglutide promotes the transition of microglia from M1 to M2 type to reduce brain inflammation in APP/PS1/tau mice.
- Exendin-4 Improves Diabetic Kidney Disease in C57BL/6 Mice Independent of Brown Adipose Tissue Activation.
- Medicinal Plants Qua Glucagon-Like Peptide-1 Secretagogue via Intestinal Nutrient Sensors.
- Liraglutide Improves PCOS Symptoms in Rats by Targeting FDX1.